Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiologí
暂无分享,去创建一个
G. Lip | I. V. Van Gelder | B. Gorenek | G. Boriani | L. Fauchier | T. Potpara | B. Williams | A. Oto | G. de Simone | A. Manolis | C. Chiang | T. Kahan | M. Olsen | D. Lovic | F. Marín | W. Tzou | Young-Hoon Kim | S. Erdine | R. Hatala | A. Coca | I. Savelieva | J. Steffel | G. Dan | Wendy S. Tzou | M. J. de Oliveira Figueiredo | J. Brguljan-Hitij | Jorge Salinas-Arce | Michael Field | Jana Brguljan-Hitij | Young-Hoon Kim
[1] J. C. Christiansen,et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. , 2020, Annals of internal medicine.
[2] P. Kirchhof,et al. [2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS]. , 2016, Kardiologia polska.
[3] F. Cosío,et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[4] G. Lip,et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[5] G. Lip. Atrial Fibrillation in Patients With Hypertension: Trajectories of Risk Factors in Yet Another Manifestation of Hypertensive Target Organ Damage. , 2016, HYPERTENSION.
[6] D. Lane,et al. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores , 2016, Journal of thrombosis and haemostasis : JTH.
[7] Hans Eiskjær,et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.
[8] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.
[9] B. Davis,et al. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. , 2016, JAMA internal medicine.
[10] R. Shi,et al. Arterial Stiffness, Central Pulsatile Hemodynamic Load, and Orthostatic Hypotension , 2016, The Journal of Clinical Hypertension.
[11] L. Fauchier,et al. Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA2DS2-VASc Risk Factor Be Anticoagulated? , 2016, Stroke.
[12] B. Olshansky,et al. Conventional management of inappropriate sinus tachycardia , 2016, Journal of Interventional Cardiac Electrophysiology.
[13] A. Camm,et al. Catheter ablation vs. antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia: a randomized, controlled trial , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[14] G. Lip,et al. Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated?: Yes Even 1 Stroke Risk Factor Confers a Real Risk of Stroke , 2016, Circulation.
[15] Hugh Calkins,et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2016, Circulation.
[16] Hugh Calkins,et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2016, Heart rhythm.
[17] S. Anderson,et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.
[18] D. Gladstone,et al. The Risk Stratification and Stroke Prevention Therapy Care Gap in Canadian Atrial Fibrillation Patients. , 2016, The Canadian journal of cardiology.
[19] G. Lip,et al. Stroke prevention in atrial fibrillation and ‘real world’ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey , 2016, Scientific Reports.
[20] C. O’Seaghdha,et al. Single Agent Antihypertensive Therapy and Orthostatic Blood Pressure Behaviour in Older Adults Using Beat-to-Beat Measurements: The Irish Longitudinal Study on Ageing , 2016, PloS one.
[21] R. de Caterina,et al. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial , 2015, Journal of the American Heart Association.
[22] F. Veglio,et al. Cardiac Organ Damage and Arterial Stiffness in Autonomic Failure: Comparison With Essential Hypertension. , 2015, Hypertension.
[23] G. de Simone,et al. Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: the Campania Salute Network. , 2015, International journal of cardiology.
[24] S. Yusuf,et al. Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). , 2015, The American journal of cardiology.
[25] S. Raj,et al. Orthostatic hypotension: managing a difficult problem , 2015, Expert review of cardiovascular therapy.
[26] Young-Soo Lee. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. , 2015 .
[27] R. Mahajan,et al. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. , 2015, Journal of the American College of Cardiology.
[28] G. Lip,et al. Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation , 2015, Stroke.
[29] R. de Caterina,et al. Orthostatic Hypotension: Epidemiology, Prognosis, and Treatment. , 2015, Journal of the American College of Cardiology.
[30] O. Nielsen,et al. Excessive Atrial Ectopy and Short Atrial Runs Increase the Risk of Stroke Beyond Incident Atrial Fibrillation. , 2015, Journal of the American College of Cardiology.
[31] P. Low,et al. Orthostatic Hypotension: Mechanisms, Causes, Management , 2015, Journal of clinical neurology.
[32] R. Bai,et al. HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. , 2015, Heart rhythm.
[33] A. Moss,et al. Improving clinical practice guidelines for practicing cardiologists. , 2015, The American journal of cardiology.
[34] O. Melander,et al. Orthostatic Changes in Hemodynamics and Cardiovascular Biomarkers in Dysautonomic Patients , 2015, PloS one.
[35] G. Lip,et al. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Pilot survey on Atrial Fibrillation , 2015, European journal of heart failure.
[36] Xu-Jiao Chen,et al. Uncontrolled hypertension and orthostatic hypotension in relation to standing balance in elderly hypertensive patients , 2015, Clinical interventions in aging.
[37] J. Halperin,et al. Fibrotic atrial cardiomyopathy, atrial fibrillation, and thromboembolism: mechanistic links and clinical inferences. , 2015, Journal of the American College of Cardiology.
[38] D. Capodanno,et al. Ventricular arrhythmias in aortic valve stenosis before and after transcatheter aortic valve implantation. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[39] M. Rosenqvist,et al. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study , 2015, Circulation.
[40] G. Lip,et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. , 2015, Journal of the American College of Cardiology.
[41] Frank Bogun,et al. Effect of ablation of frequent premature ventricular complexes on left ventricular function in patients with nonischemic cardiomyopathy. , 2015, Heart rhythm.
[42] David J. Gladstone,et al. Atrial Premature Beats Predict Atrial Fibrillation in Cryptogenic Stroke: Results From the EMBRACE Trial , 2015, Stroke.
[43] P. Deedwania,et al. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. , 2015, The American journal of medicine.
[44] A. Oto,et al. A Prospective DE‐MRI Study Evaluating the Role of TGF‐β1 in Left Atrial Fibrosis and Implications for Outcomes of Cryoballoon‐Based Catheter Ablation: New Insights into Primary Fibrotic Atriocardiomyopathy , 2015, Journal of cardiovascular electrophysiology.
[45] T. Chao,et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? , 2015, Journal of the American College of Cardiology.
[46] G. Lip,et al. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[47] T. Grodzicki,et al. Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. , 2014, The American journal of cardiology.
[48] John Sapp,et al. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias , 2014, Heart rhythm.
[49] T. Potpara,et al. Diving to the foot of an iceberg: The SEARCH for undiagnosed atrial fibrillation , 2014, Thrombosis and Haemostasis.
[50] A. Capucci,et al. Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events , 2014, Circulation.
[51] D. Singer,et al. Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2014, Circulation.
[52] B. Nordestgaard,et al. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. , 2014, European heart journal.
[53] S. Tobe,et al. Combining other antihypertensive drugs with β-blockers in hypertension: a focus on safety and tolerability. , 2014, The Canadian journal of cardiology.
[54] N. Lowres,et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies , 2014, Thrombosis and Haemostasis.
[55] A. Parkhomenko,et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.
[56] P. Kirchhof,et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[57] G. Lip,et al. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation , 2014, European heart journal.
[58] I. Durand-zaleski,et al. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[59] Mukul Sharma,et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation , 2013, Thrombosis and Haemostasis.
[60] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[61] G. Lip,et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. , 2013, Chest.
[62] G. Lip,et al. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. , 2013, International journal of cardiology.
[63] G. Lip,et al. Cost Effectiveness of Treatments for Stroke Prevention in Atrial Fibrillation: Focus on the Novel Oral Anticoagulants , 2013, PharmacoEconomics.
[64] V. Roger,et al. Temporal Relationship and Prognostic Significance of Atrial Fibrillation in Heart Failure Patients With Preserved Ejection Fraction: A Community-Based Study , 2013, Circulation.
[65] Simon Stewart,et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. , 2013, International journal of cardiology.
[66] K. Swedberg,et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. , 2013, European heart journal.
[67] J. Barthélémy,et al. Sympathetic overactivity due to sleep fragmentation is associated with elevated diurnal systolic blood pressure in healthy elderly subjects: the PROOF-SYNAPSE study. , 2013, European heart journal.
[68] Jeroen J. Bax,et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2013, European heart journal.
[69] P. Kirchhof,et al. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. , 2013, European heart journal.
[70] Daniel E. Singer,et al. A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score , 2013, Journal of the American Heart Association.
[71] G. Lip,et al. Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry , 2013, PloS one.
[72] A. Uy‐Evanado,et al. Electrocardiographic Predictors of Sudden Cardiac Death in Patients with Left Ventricular Hypertrophy , 2013, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.
[73] Julie Redfern,et al. Screening to identify unknown atrial fibrillation , 2013, Thrombosis and Haemostasis.
[74] Prashanthan Sanders,et al. Long‐term Outcomes of Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta‐analysis , 2013, Journal of the American Heart Association.
[75] David D. McManus,et al. Simple Risk Model Predicts Incidence of Atrial Fibrillation in a Racially and Geographically Diverse Population: the CHARGE‐AF Consortium , 2013, Journal of the American Heart Association.
[76] E. Lo,et al. Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies , 2013, The Lancet Neurology.
[77] I. V. Van Gelder,et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. , 2013, JACC. Heart failure.
[78] David C. Wheeler,et al. Notice , 2012, Kidney International Supplements.
[79] Gerhard Hindricks,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[80] Kazuomi Kario,et al. Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension. , 2012, American journal of hypertension.
[81] Habib Gamra,et al. Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice: Insight From the Real-Life Global Survey Evaluating Patients With Atrial Fibrillation International Registry , 2012, Circulation. Arrhythmia and electrophysiology.
[82] G. Lip,et al. Net Clinical Benefit of Warfarin in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study , 2012, Circulation.
[83] G. Lip,et al. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. , 2012, Chest.
[84] K. Liestøl,et al. Upper Normal Blood Pressures Predict Incident Atrial Fibrillation in Healthy Middle-Aged Men: A 35-Year Follow-Up Study , 2012, Hypertension.
[85] A. Capucci,et al. Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.
[86] E. Dolan,et al. Improved Late Survival and Disability After Stroke With Therapeutic Anticoagulation for Atrial Fibrillation: A Population Study , 2011, Stroke.
[87] J. Tolstrup,et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.
[88] D. Singer,et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.
[89] G. Lip,et al. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[90] Hidayet Kayançiçek,et al. Assessment of atrial conduction time in patients with essential hypertension. , 2011, Journal of electrocardiology.
[91] R. Vasan,et al. Epidemiology and clinical course of heart failure with preserved ejection fraction , 2011, European journal of heart failure.
[92] D. Singer,et al. Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation , 2011, Circulation. Cardiovascular quality and outcomes.
[93] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[94] G. Boriani,et al. Role of drugs and devices in patients at risk of sudden cardiac death , 2010, Fundamental & clinical pharmacology.
[95] O. Osadchii. Mechanisms of hypokalemia‐induced ventricular arrhythmogenicity , 2010, Fundamental & clinical pharmacology.
[96] V. Pyrgakis,et al. Evaluation of left ventricular hypertrophy in patients requiring permanent pacing , 2010, Therapeutic advances in cardiovascular disease.
[97] Frank Bogun,et al. Relationship between burden of premature ventricular complexes and left ventricular function. , 2010, Heart rhythm.
[98] K. Nagata,et al. Blood Pressure Levels and Bleeding Events During Antithrombotic Therapy: The Bleeding With Antithrombotic Therapy (BAT) Study , 2010, Stroke.
[99] L. Køber,et al. Excessive Supraventricular Ectopic Activity and Increased Risk of Atrial Fibrillation and Stroke , 2010, Circulation.
[100] Robby Nieuwlaat,et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. , 2010, Journal of the American College of Cardiology.
[101] B. Howard,et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study , 2010, Journal of hypertension.
[102] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[103] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[104] Daniel P. Morin,et al. QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study. , 2009, European heart journal.
[105] D. Liao,et al. Abstract 1328: Premature Cardiac Contractions and Risk of Incident Ischemic Stroke , 2009 .
[106] L. Thijs,et al. Regression of Left Ventricular Mass by Antihypertensive Treatment: A Meta-Analysis of Randomized Comparative Studies , 2009, Hypertension.
[107] K. Fukuda,et al. Cardiac Innervation and Sudden Cardiac Death , 2009, Current cardiology reviews.
[108] M. Law,et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.
[109] C. Albert,et al. Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women , 2009, Circulation.
[110] D. Levy,et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study , 2009, The Lancet.
[111] H. Crijns,et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. , 2008, JAMA.
[112] T. Lumley,et al. Blood pressure control and risk of incident atrial fibrillation. , 2008, American journal of hypertension.
[113] R. Ferrari,et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial , 2008, The Lancet.
[114] Adelaide M. Arruda-Olson,et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Coun , 2008, Journal of the American College of Cardiology.
[115] M. Nieminen,et al. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study , 2008, Journal of hypertension.
[116] Harlan M Krumholz,et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Journal of the American College of Cardiology.
[117] Marmar Vaseghi,et al. The role of the autonomic nervous system in sudden cardiac death. , 2008, Progress in cardiovascular diseases.
[118] H. Tse,et al. Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications , 2008, Journal of Human Hypertension.
[119] T. Ogihara,et al. Effects of Candesartan Compared With Amlodipine in Hypertensive Patients With High Cardiovascular Risks: Candesartan Antihypertensive Survival Evaluation in Japan Trial , 2008, Hypertension.
[120] G. Lip,et al. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.
[121] C. Pepine,et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). , 2007, European heart journal.
[122] G. Lip,et al. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. , 2007, QJM : monthly journal of the Association of Physicians.
[123] Jean-Claude Tardif,et al. Resting heart rate in cardiovascular disease. , 2007, Journal of the American College of Cardiology.
[124] M. Nieminen,et al. Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death: The LIFE Study , 2007, Circulation.
[125] Independent predictors of stroke in patients with atrial fibrillation , 2007, Neurology.
[126] D. Singer,et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. , 2007, The American journal of medicine.
[127] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[128] G. Lip,et al. Effect of hypertension on anticoagulated patients with atrial fibrillation. , 2007, European heart journal.
[129] S. Willich,et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[130] H. Crijns,et al. Enhanced cardiovascular morbidity and mortality during rhythm control treatment in persistent atrial fibrillation in hypertensives: data of the RACE study. , 2007, European heart journal.
[131] M. Rich,et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.
[132] R. Tieleman,et al. Atrial extrasystoles after exercise predict atrial fibrillation in patients with left ventricular hypertrophy , 2005, Heart.
[133] T. Kahan,et al. Left ventricular hypertrophy in hypertension: its arrhythmogenic potential , 2005, Heart.
[134] I. V. Van Gelder,et al. Rate control in atrial fibrillation. , 2004, Journal of the American College of Cardiology.
[135] Lauri Toivonen,et al. QRS Duration and QT Interval Predict Mortality in Hypertensive Patients With Left Ventricular Hypertrophy: The Losartan Intervention for Endpoint Reduction in Hypertension Study , 2004, Hypertension.
[136] S. Priori,et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing co , 2003, Journal of the American College of Cardiology.
[137] W. DuMouchel,et al. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post‐marketing setting , 2003, Pharmacoepidemiology and drug safety.
[138] A. Waldo. Stroke prevention in atrial fibrillation. , 2003, JAMA.
[139] K. Borch-Johnsen,et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study , 2003, The Lancet.
[140] W. Elliott,et al. The Economic Impact of Hypertension , 2003, Journal of clinical hypertension.
[141] Maurizio Bentivoglio,et al. Atrial Fibrillation in Hypertension: Predictors and Outcome , 2003, Hypertension.
[142] T. Kahan,et al. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). , 2002, The American journal of cardiology.
[143] S. Mochizuki,et al. Hypertension‐Related Intermyocyte Junction Remodelling is Associated with a Higher Incidence of Low‐K+‐Induced Lethal Arrhythmias in Isolated Rat Heart , 2002, Experimental physiology.
[144] M. Rich,et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. , 2001, JAMA.
[145] S. Borzak,et al. Pharmacologic conversion of atrial fibrillation: a systematic review of available evidence. , 2001, Progress in cardiovascular diseases.
[146] P Lavie,et al. Obstructive Sleep Apnea and Hypertension: From Correlative to Causative Relationship , 2001, Journal of clinical hypertension.
[147] M. Barbagallo,et al. Effects of drug therapy on cardiac arrhythmias and ischemia in hypertensives with LVH. , 2001, American journal of hypertension.
[148] A. Oksenberg,et al. Are sleep-related breathing disorders important contributing factors to the production of essential hypertension? , 2001, Current hypertension reports.
[149] S. Hohnloser,et al. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial , 2000, The Lancet.
[150] K. Umetani,et al. Cardiac arrhythmias and left ventricular hypertrophy in dipper and nondipper patients with essential hypertension. , 2000, Japanese circulation journal.
[151] W. Kannel,et al. Vital epidemiologic clues in heart failure. , 2000, Journal of clinical epidemiology.
[152] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[153] F. Messerli. Hypertension and sudden cardiac death. , 1999, American journal of hypertension.
[154] A. Saadeh,et al. QTc dispersion and complex ventricular arrhythmias in untreated newly presenting hypertensive patients , 1999, Journal of Human Hypertension.
[155] D. Levy,et al. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. , 1998, Journal of the American College of Cardiology.
[156] P A Wolf,et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. , 1998, The American journal of cardiology.
[157] H. Gavras,et al. Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity. , 1998, American journal of hypertension.
[158] S. Boveda,et al. Prognostic value of ventricular arrhythmias in systemic hypertension , 1997, Journal of hypertension.
[159] M. Barbagallo,et al. Increased prevalence of cardiac arrhythmias and transient episodes of myocardial ischemia in hypertensives with left ventricular hypertrophy but without clinical history of coronary heart disease. , 1997, American journal of hypertension.
[160] S. Thom,et al. The effects on cardiac arrhythmias of antihypertensive therapy causing regression of left ventricular hypertrophy. , 1997, American Journal of Hypertension.
[161] R. Ajisaka,et al. Alterations in left ventricular wall stress and coronary circulation in patients with isolated systolic hypertension , 1996, Journal of hypertension.
[162] T. Raghunathan,et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. , 1994, The New England journal of medicine.
[163] D. Sideris. High blood pressure and ventricular arrhythmias. , 1993, European heart journal.
[164] S. Hohnloser,et al. Prevalence of Circadian Variations and Spontaneous Variabilit of Cardiac Disorders and ECG Changes Suggestive of Myocardial Ischemia in Systemic Arterial Hypertension , 1992, Circulation.
[165] P. Macfarlane,et al. Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. , 1992, The American journal of cardiology.
[166] S B Hulley,et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. , 1992, JAMA.
[167] H. Calkins,et al. Effect of acute volume load on refractoriness and arrhythmia development in isolated, chronically infarcted canine hearts. , 1989, Circulation.
[168] N. Kaplan. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. , 1988 .
[169] D. Levy,et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. , 1987, The American journal of cardiology.
[170] R. Kleiger,et al. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. , 1986, The New England journal of medicine.
[171] W. Kannel,et al. Sudden death: lessons from subsets in population studies. , 1985, Journal of the American College of Cardiology.
[172] E. Bixler,et al. SLEEP APNOEA IN A HYPERTENSIVE POPULATION , 1984, The Lancet.
[173] S. Kawai,et al. Histopathology of the conduction system in sudden cardiac death. , 1983, Japanese circulation journal.
[174] U. Schotten,et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation , 2017, European heart journal.
[175] F. Cosío,et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[176] Andrea Mazzanti,et al. [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]. , 2015, Kardiologia polska.
[177] P. Lantelme,et al. Significance, prognostic value and management of heart rate in hypertension. , 2014, Archives of cardiovascular diseases.
[178] Kyle W. Klarich,et al. Premature Ventricular Contraction-Induced Cardiomyopathy: A Treatable Condition , 2012, Circulation. Arrhythmia and electrophysiology.
[179] D. Xavier,et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[180] Karly P Garnock-jones. Esmolol , 2012, Drugs.
[181] Elsayed Z Soliman,et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). , 2011, The American journal of cardiology.
[182] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[183] M. Wright,et al. Controversies in cardiovascular medicine Drugs vs . ablation for the treatment of atrial fibrillation : the evidence supporting catheter ablation , 2010 .
[184] G. De Luca,et al. "Meta-analysis of ablation of atrial flutter and supraventricular tachycardia". , 2010, The American journal of cardiology.
[185] Claudia Stöllberger,et al. Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.
[186] N. Tribulova,et al. Adaptation of the heart to hypertension is associated with maladaptive gap junction connexin-43 remodeling. , 2008, Physiological research.
[187] Jeroen J. Bax,et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.
[188] D. Faxon,et al. Guidelines for the Management of Patients With Supraventricular Arrhythmias * — Executive Summary , 2003 .
[189] D. Faxon,et al. Tomaselli Gf. Acc/aha/esc Guidelines for the Management of Patients with Supraventricular Arrhythmias: a Report of the American College of Cardiology/american Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing Committ , 2022 .
[190] G. Heiss,et al. Association of ventricular premature complexes with electrocardiographic-estimated left ventricular mass in a population of African-American and white men and women (The Atherosclerosis Risk in Communities. , 2001, The American journal of cardiology.
[191] A. Kitsiou,et al. The circadian profile of extrasystolic arrhythmia: its relationship to heart rate and blood pressure. , 1992, International journal of cardiology.
[192] J. Lumme,et al. Cardiac arrhythmias in hypertensive outpatients on various diuretics. Correlation between incidence and serum potassium and magnesium levels. , 1986, Annals of clinical research.
[193] G. Lip,et al. Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin The SAMe-TT 2 R 2 Score , 2022 .